These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8493988)

  • 1. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study.
    Bray GL; Kroner BL; Arkin S; Aledort LW; Hilgartner MW; Eyster ME; Ragni MV; Goedert JJ
    Am J Hematol; 1993 Apr; 42(4):375-9. PubMed ID: 8493988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.
    Batlle J; Gómez E; Rendal E; Torea J; Lourés E; Couselo M; Vila P; Sedano C; Tusell X; Magallón M; Quintana M; González-Boullosa R; López-Fernández MF
    Ann Hematol; 1996 May; 72(5):321-6. PubMed ID: 8645745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
    Peyvandi F; Mannucci PM; Garagiola I; El-Beshlawy A; Elalfy M; Ramanan V; Eshghi P; Hanagavadi S; Varadarajan R; Karimi M; Manglani MV; Ross C; Young G; Seth T; Apte S; Nayak DM; Santagostino E; Mancuso ME; Sandoval Gonzalez AC; Mahlangu JN; Bonanad Boix S; Cerqueira M; Ewing NP; Male C; Owaidah T; Soto Arellano V; Kobrinsky NL; Majumdar S; Perez Garrido R; Sachdeva A; Simpson M; Thomas M; Zanon E; Antmen B; Kavakli K; Manco-Johnson MJ; Martinez M; Marzouka E; Mazzucconi MG; Neme D; Palomo Bravo A; Paredes Aguilera R; Prezotti A; Schmitt K; Wicklund BM; Zulfikar B; Rosendaal FR
    N Engl J Med; 2016 May; 374(21):2054-64. PubMed ID: 27223147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII inhibitor developed in a 60-year-old patient with mild hemophilia A after surgery for colon cancer.
    Suzuki T; Arai M; Miyasaka S; Watanabe J; Sugimura D; Amano K; Yamagishi T; Kagawa K; Fukue H; Fukutake K
    Int J Hematol; 1995 Aug; 62(2):127-32. PubMed ID: 8590774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern of factor VIII inhibitors in patients with hemophilia A in the north east of Iran.
    Modaresi AR; Torghabeh HM; Pourfathollah AA; Shooshtari MM; Yazdi ZR
    Hematology; 2006 Jun; 11(3):215-7. PubMed ID: 17325965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine.
    Ambriz Fernandez R; Quintana Gonzalez S; Martinez Murillo C; Dominguez Garcia V; Rodriguez Moyado H; Collazo Jaloma J
    Arch Med Res; 1996; 27(1):15-8. PubMed ID: 8867361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
    Kreuz W; Becker S; Lenz E; Martinez-Saguer I; Escuriola-Ettingshausen C; Funk M; Ehrenforth S; Auerswald G; Kornhuber B
    Semin Thromb Hemost; 1995; 21(4):382-9. PubMed ID: 8747701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
    Mannucci PM
    Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune tolerance by intermittent factor VIII boluses in two high responder hemophilia A patients.
    Landolfi R; de Cristofaro R; Lazzareschi I; Riccardi R; Mariani G
    Haematologica; 2000 Oct; 85(10 Suppl):73-4. PubMed ID: 11187877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
    Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between factor VIII genotype and inhibitor development in hemophilia A.
    Fakharzadeh SS; Kazazian HH
    Semin Thromb Hemost; 2000; 26(2):167-71. PubMed ID: 10919409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Porcine factor VIII provides clinical benefit to patients with high levels of inhibitors to human and porcine factor VIII.
    Gribble J; Garvey MB
    Haemophilia; 2000 Sep; 6(5):482-5. PubMed ID: 11012689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
    Mariani G; Kroner B;
    Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin.
    Santagostino E; Gringeri A; Tagliavacca L; Mannucci PM
    Thromb Haemost; 1995 Aug; 74(2):619-21. PubMed ID: 8584995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
    Calvez T; Chambost H; d'Oiron R; Dalibard V; Demiguel V; Doncarli A; Gruel Y; Huguenin Y; Lutz P; Rothschild C; Vinciguerra C; Goudemand J;
    Haematologica; 2018 Jan; 103(1):179-189. PubMed ID: 29025913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors.
    Ewing NP; Sanders NL; Dietrich SL; Kasper CK
    JAMA; 1988 Jan; 259(1):65-8. PubMed ID: 3119878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.